±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1186  |  »Ø¸´: 4

zrm

ľ³æ (СÓÐÃûÆø)

[½»Á÷] ¡¾ÇóÖú¡¿ÃÀ¹úÒ©µä33°æ ÒÑÓÐ3È˲ÎÓë

ÓÐÃÀ¹úÒ©µä33°æµÄÄÜ·ñ°ïÎÒ²éÏÂË«±ûÎìËáÄÆµÄ±ê×¼£¬Ð»Ð»£¡£¡£¡£¡
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Ò»Ö»ºÃÈË

½ð³æ (СÓÐÃûÆø)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ͬÇó£¡Í¬Ç󣡼±Óùþ!Ëͽð±Ò10¸ö
2Â¥2011-08-04 09:57:50
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Ò»Ö»ºÃÈË

½ð³æ (СÓÐÃûÆø)

×Ô¼º¶¥ÆðÀ´ºÇºÇ
3Â¥2011-08-04 09:59:42
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kongkong75

½ð³æ (СÓÐÃûÆø)

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
warlen(½ð±Ò+1): лл²ÎÓë 2011-08-05 10:05:51
Divalproex Sodium
(dye val' proe ex soe' dee um)

(C16H31NaO4)n
310.41
Pentanoic acid, 2-propyl-, sodium salt (2:1);     
Sodium hydrogen bis(2-propylvalerate) oligomer     
DEFINITION
Divalproex Sodium contains NLT 98.0% and NMT 102.0% of available valproic acid (C8H16O2).
IDENTIFICATION
•  A. Infrared Absorption 197K
•  B. Identification Tests¡ªGeneral, Sodium 191: Ignite 100 mg.
ASSAY
•  Procedure
Solution A:  3.5 g of monobasic sodium phosphate monohydrate in 900 mL of water. Adjust with phosphoric acid to a pH of 3.5. Dilute with water to 1 L.
Mobile phase:  Acetonitrile and Solution A (1:1)
Standard stock solution:  5.0 µg/mL of USP Valproic Acid RS in Mobile phase
Standard solution:  0.5 mg/mL of USP Valproic Acid RS, from Standard stock solution in Mobile phase
Impurity stock solution:  0.5 mg/mL of USP Valproic Acid Related Compound A RS in acetonitrile
System suitability solution:  0.5 mg/mL of valproic acid, from Standard stock solution, and 5 µg/mL of valproic acid related compound A, from Impurity stock solution, in Mobile phase
Sample solution:  0.5 mg/mL of Divalproex Sodium in Mobile phase
Chromatographic system  
(See Chromatography 621, System Suitability.)
Mode:  LC
Detector:  UV 215 nm
Column:  4.6-mm ¡Á 15-cm; 5-µm packing L7
Flow rate:  1 mL/min
Injection size:  20 µL
System suitability  
Sample:  System suitability solution
[Note¡ªThe relative retention times for valproic acid related compound A and valproic acid are 0.69 and 1.0, respectively. ]
Suitability requirements  
Resolution:  NLT 5.0 between valproic acid related compound A and valproic acid
Tailing factor:  NMT 1.5 for the valproic acid peak
Relative standard deviation:  NMT 2.0%
Analysis  
Samples:  Standard solution and Sample solution
Calculate the percentage of C8H16O2) in the portion of Divalproex Sodium taken:
Result = (rU/rS) ¡Á (CS/CU) ¡Á (Mr1/Mr2) ¡Á (1/F) ¡Á 100
rU = = peak area from the Sample solution
rS = = peak area from the Standard solution
CS = = concentration of USP Valproic Acid RS in the Standard solution (mg/mL)
CU = = concentration of the Sample solution (mg/mL)
Mr1 = = molecular weight for divalproex sodium repeating unit, 310.41
Mr2 = = molecular weight for valproic acid, 144.21
F = = number of moles of valproic acid/mole of divalproex sodium repeating unit, 2  

Acceptance criteria:  98.0%¨C102.0%
IMPURITIES
Inorganic Impurities  
•  Heavy Metals, Method II 231: NMT 20 ppm
SPECIFIC TESTS
•  Water Determination, Method I 921: NMT 1.0%, determined on 3.0 g
ADDITIONAL REQUIREMENTS
•  Packaging and Storage: Preserve in tight containers. Store at room temperature
•  USP Reference Standards 11
USP Divalproex Sodium RS  
USP Valproic Acid RS  
USP Valproic Acid Related Compound A RS  
Auxiliary Information¡ª Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ravi Ravichandran, Ph.D.
Senior Scientist
1-301-816-8330 (MDPP05) Monograph Development-Psychiatrics and Psychoactives
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org  

USP33¨CNF28 Page 2830
Pharmacopeial Forum: Volume No. 32(6) Page 1675
Chromatographic Column¡ª  
DIVALPROEX SODIUM
Chromatographic columns text is not derived from, and not part of, USP 33 or NF 28.
ÐÂÒ©Ñз¢¡¢×¢²áÉ걨¡¢Ò©Æ··¨¹æµÈÏà¹Ø×îÐÂÐÅÏ¢×Éѯ£¬ÇëÁªÏµQQ£º609195969
4Â¥2011-08-04 21:41:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÎÄÉÙ520

½ð³æ (ÕýʽдÊÖ)

ͬÇó£¡Í¬Çó£¡
ÎÒÊÇС³æ£¬ÎÒÒªÉý¼¶
5Â¥2012-07-19 10:14:22
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ zrm µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸ÏÃÃÅ´óѧ£¬ÉúÎïÓëÒ½Ò©£¬×Ü·Ö272£¬±¾¿Æ211 +3 Electron1cc 2026-04-01 4/200 2026-04-05 20:24 by lys0704
[¿¼ÑÐ] Çóµ÷¼Á Ò»Ö¾Ô¸Î÷ÄϽ»Í¨´óѧ085701»·¾³¹¤³Ì 282·Ö +7 ¶à¶à°®³Ôºº±¤ 2026-04-04 7/350 2026-04-05 19:47 by ¸£Å©×Ê»·_»·¾³»ù
[¿¼ÑÐ] Ò»Ö¾Ô¸211ÉúÎïѧ280·Ö Çóµ÷¼Á +4 Àîrien 2026-04-05 4/200 2026-04-05 18:01 by kk112233
[¿¼ÑÐ] 270·ÖÇóµ÷¼Á +4 maxjxbsk 2026-04-01 4/200 2026-04-05 17:04 by yulian1987
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 mcbbc 2026-04-04 3/150 2026-04-05 10:03 by barlinike
[¿¼ÑÐ] ÄÐÉú£¬Ò»Ö¾Ô¸»¦9ÉúÎïѧ071000£¬³õÊÔ308Çóµ÷¼Á +3 Áõīī 2026-04-04 3/150 2026-04-05 08:26 by barlinike
[¿¼ÑÐ] 085600£¬321·ÖÇóµ÷¼Á +10 ´ó²öС×Ó 2026-04-04 11/550 2026-04-05 08:25 by 544594351
[¿¼ÑÐ] 311·Ö 22408 Çóµ÷¼Á +3 bing_bot 2026-04-03 3/150 2026-04-05 00:43 by chongya
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£´ó0705Çóµ÷¼Á +3 éÙʮһ 2026-04-02 4/200 2026-04-05 00:05 by chongya
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +18 Ò»ÑùYWY 2026-04-02 19/950 2026-04-04 22:14 by hemengdong
[¿¼ÑÐ] ²ÄÁÏרҵ383Çóµ÷¼Á +8 ¹ùÑôÑôÑô³É 2026-04-03 8/400 2026-04-04 10:29 by Rednal.
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸±±Àí325·ÖÇóµ÷¼Á +6 ÕÒµ÷¼Á£¬£¬ 2026-04-02 6/300 2026-04-03 22:20 by –¹Æ?
[»ù½ðÉêÇë] ÇëÎʹ²Í¬Í¨Ñ¶ºÍ¹²Í¬Ò»×÷µÄÈϿɶÈÎÊÌâ 10+4 psa1234 2026-04-01 10/500 2026-04-03 11:08 by Kittylucky
[¿¼ÑÐ] ÖØÇì´óѧ²ÄÁÏÓ뻯¹¤085600£¬³õÊÔ370+£¬ÇóÇóµ÷¼Á½¨Òé +8 shzhou_ 2026-04-01 9/450 2026-04-03 09:31 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 0856²ÄÁÏÓ뻯¹¤µ÷¼Á£¬339 +14 10213207 2026-03-31 14/700 2026-04-02 21:01 by 1104338198
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ +6 whatÕÅ 2026-04-01 7/350 2026-04-02 16:48 by zzsw+
[¿¼ÑÐ] ¿¼Ñе÷¼Á +12 Amber00 2026-03-31 12/600 2026-04-02 09:04 by sanrepian
[¿¼ÑÐ] 311Çóµ÷¼Á +10 ÀîÜÆÐÂ1 2026-03-31 10/500 2026-04-01 14:38 by chenqifeng666
[¿¼ÑÐ] 0710ÉúÎïѧÇóµ÷¼Á£¡ +6 ÐðÊöÎÄ 2026-03-31 6/300 2026-04-01 09:39 by JourneyLucky
[¿¼ÑÐ] 293Çóµ÷¼Á +3 ĩδmm 2026-03-30 5/250 2026-03-30 17:23 by Íõ±£½Ü33
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û